The middle tumor antigen (middle-T) of mouse polyomavirus is responsible for the transforming potential of this virus. Middle-T has been shown to interact with a variety of cellular proteins known to mediate mitogenic signaling, like phosphatase-2A, Src family kinases, phosphatidylinositol 3-kinase (PI 3-kinase), the adapter protein SHC, phospholipase Cg-1 and 14-3-3 family proteins. Association with SHC and PI 3-kinase, respectively, stimulates two independent signaling pathways that are indispensible for viral oncogenicity. SHC activates the Ras/MAPK pathway via Grb2/SOS resulting in changes in early gene expression. The downstream targets of PI 3-kinase are less well studied but seem to impinge on serum response factor (SRF) which is also involved in regulating early gene expression. Recently, the protein kinase B/Akt (PKB/Akt) has been identi®ed as a target of PI 3-kinase in receptor tyrosine kinase signaling. Here we show that PKB/Akt is a target of wild type middle-T, but not of mutants unable to activate PI 3-kinase. These data were con®rmed using inhibitors of PI 3-kinase as well as dominant-negative alleles of the catalytic subunit of this lipid kinase. In addition, mutants of PKB/Akt lacking a pleckstrin homology domain and therefore unable to bind to D3 phospatidylinositides were not activated by middle-T. Taken together these data suggest that middle-T activates PKB/Akt in a PI 3-kinase-dependent manner. Furthermore, direct association with D3 phosphatidylinositides seems to be essential for activation of PKB/ Akt.
Introduction
Mouse polyomavirus induces a broad spectrum of tumors in mice and transforms cells in culture (Treisman et al., 1981; Rassoulzadegan et al., 1982) . The viral proteins mediating this function are the tumor antigens, in particular the middle-T antigen. Oncogenic transformation by polyomavirus has been used as a paradigm for the study of mitogenic signaling in mammalian cells since this protein activates many of the cellular pathways also targeted by tyrosine kinase growth factor receptors. Signaling by middle-T requires interactions with cellular proteins such as the serine/ threonine protein phosphatase 2A (PP2A) (Pallas et al., 1990; Walter et al., 1990) , Src family tyrosine kinases (Courtneidge and Smith, 1983 and reviewed in Kiefer et al., 1994) , the adaptor protein SHC which binds to phosphotyrosine 250 of middle-T via its phosphotyrosine binding (PTB) domain (Dilworth et al., 1994; Campbell et al., 1994) , PI 3-kinase (Whitman et al., 1985; Talmage et al., 1989; Courtneidge et al., 1989) and phospholipase Cg-1 (Su et al., 1995) . When associated with middle-T, SHC gets phosphorylated at tyrosine residues. This renders this protein competent to initiate downstream signaling through Grb2 and SOS resulting in increased GTP loading of Ras. Activated Ras propagates and presumably ampli®es incoming signals and initiates the MAP kinase cascade (Robinson and Cobb, 1997) . Association of PI 3-kinase with tyrosine kinase receptors or middle-T leads to activation of this enzyme, resulting in increased production of D3 phosphatidylinositides. These lipids have been implicated in the regulation of a plethora of cellular phenomena such as cell growth, rearrangement of cytoskeletal structures, cellular motility, receptor tracking, cell survival and chemotaxis (reviewed in Toker and . Recent work shows that these lipids undergo speci®c interactions with target proteins having SH2- (Rameh et al., 1995) or PH-domains (Klarlund et al., 1997; . Protein kinase B/Akt (PKB/Akt), also known as RAC-PK, is one of these targets and is activated in response to growth stimulation (Franke et al., 1995) . The phospholipid products of PI 3-kinase bind to the PH-domain of PKB/Akt and recruit this protein to the plasma membrane. This leads to activation upon phosphorylation by a not yet identi®ed cellular kinase, presumably also located at cellular membranes (Alessi et al., 1996) . It has also been shown that PI 3-kinase is required for full activation of the Ras/MAPK pathway by middle-T as well as for signaling to serum response factor (Urich et al., 1997) . Mutants of middle-T still capable of activating PI 3-kinase, but lacking a binding site for SHC, trigger stimulation of p70 S6-kinase (Dahl et al., 1996) or p21
Rac -mediated transcriptional regulation (Urich et al., 1997) .
Results

Middle-T activates PKB/Akt
To determine the eect of middle-T on PKB/Akt activity, a HA-tagged version of this kinase was transiently expressed together with middle-T in NIH3T3 cells. Kinase activity was measured in immunecomplex assays using histone 2B as substrate.
In the absence of serum, wild type middle-T activated PKB/Akt about 20-fold ( Figure 1a , compare lanes 1 and 2) whereas in the presence of serum activation was only twofold (Figure 1a , compare lanes 6 and 7) indicating that PKB/Akt is maintained at high enzymatic activity by serum growth factors.
PI 3-kinase but not SHC is required for PKB/Akt activation by middle-T Mutants of middle-T were used to further de®ne the requirements for PKB/Akt activation. The mutant Y315F, which does not bind p85 and therefore cannot activate PI 3-kinase, was unable to activate PKB/Akt (Figure 1a , lanes 5 and 9 and 1b, bar 4). The mutant Y250F, unable to associate with SHC, activated PKB/ Akt almost to the level of wild type middle-T ( Figure  1a , lanes 4 and 8 and 1b, bar 3). The fact that this mutant was slightly less potent at activating PKB/Akt might be explained by the observation that it binds less p85 as shown earlier (Dilworth et al., 1994) (Figure 2 , compare lanes 2 and 3). Finally, the mutant dl1015 which binds p85 ( Figure 2 , lane 4), but fails to activate PI 3-kinase in vivo (Ling et al., 1992) , showed that interaction of PI 3-kinase with middle-T per se is not sucient for PKB/Akt activation ( Figure 1b , bar 5).
Additional experiments using the PI 3-kinase inhibitor LY294002 were performed to demonstrate that lipid kinase activity is essential for PKB/Akt activation. The data show that LY294002 rapidly The PH-domain of PKB/Akt is required for activation by middle-T To investigate whether the phosphoinositides produced upon activation of PI 3-kinase by middle-T are required for PKB/Akt activation, we studied the activity of a mutant of PKB/Akt, DPH-PKB/Akt, lacking a pleckstrin homology domain and therefore unable to bind D3 phosphoinositides Alessi et al., 1996) . This mutant was not activated by middle-T (Figure 4 , lanes 3 and 4). The fact that DPH-PKB/Akt was almost fully activated by the nonspeci®c tyrosine phosphatase inhibitor vanadyl hydroperoxide as previously described , con®rms that the catalytic center of the kinase domain was unaected by the deletion ( Figure  4 , lane 5). From these data we conclude that middle-T signaling to PKB/Akt is mediated by binding of D3 phosphoinositides to the PH-domain of PKB/Akt. This study identi®es PKB/Akt as a target of polyomavirus middle-T. It also shows that activation of PKB/Akt strictly depends on T antigen-associated PI 3-kinase. Our data are in agreement with the earlier proposed concept that the pleckstrin homology domain of PKB/Akt associates with D3 phosphoinositides produced by PI 3-kinase (Alessi et al., 1996; Franke et al., 1995 Franke et al., , 1997 Bos, 1995) . PKB/Akt has been shown to assume at least two functions in tissue homeostasis (Bos, 1995; . First, it is involved in mitogenic signaling and regulation of cellular kinases such as glycogen synthase kinase 3 (Cross et al., 1995) . When glycogen synthase kinase 3 is inactivated by phosphorylation, anabolic pathways are upregulated (Welsh et al., 1996) . Another kinase associated with growth factor stimulation, p70 S6-kinase , is activated by constitutively active mutants of PKB/Akt, but is not a direct substrate (Burgering and Coer, 1995) . p70 S6-kinase activation has also been observed as a consequence of polyomavirus infection (Talmage et al., 1988; Dahl et al., 1996) . The involvement of PKB/Akt in growth regulation is further supported by data obtained with an oncogenic form of PKB/Akt expressed as a Gag-PKB/Akt fusion protein by the acute retrovirus AKT8 (Bellacosa et al., 1991) . The viral Gag portion leads to membrane association and constitutive activation of this mutant kinase.
The second role of PKB/Akt is to block apoptosis, as e.g. demonstrated in cells overexpressing PKB/Akt (Dudek et al., 1997; Kennedy et al., 1997; Kulik et al., 1997) . In agreement with this concept, dominantnegative alleles of PKB/Akt block survival of starved mT wt plus Figure 3 PI 3-kinase activity is required for PKB activation. Cells were transfected as described. In lane 3, 30 ng/ml PDGF BB were added for 15 min. In lanes 4 ± 6, the inhibitor was added for 15 min prior to cell lysis at a concentration of 15 mM. Cells in lane 6 were treated with 30 ng/ml PDGF BB for 5 min before the inhibitor was added. In lanes 8,9, cells were cotransfected with a wt (p110) and an enzymatically inactive mutant form of the p110 subunit of PI 3-kinase (p110K-), respectively. The bar graph at the bottom shows the relative activities in one representative experiment cells treated with survival factors such as IGF-1 or IL-2 (Ahmed et al., 1997; Dudek et al., 1997; Kulik et al., 1997) . It has also been shown that PKB/Akt promotes survival in cells destined to enter apoptosis upon overexpression of Myc (Kaumann-Zeh et al., 1997) . Based on these data one might speculate that PKB/Akt also plays a role in the lytic cycle of many viruses where inadequate growth stimulation and viral DNA replication have been shown to eciently trigger intracellular defense mechanisms like G1 cell cycle arrest and apoptosis (reviewed in Teodoro and Branton, 1997). One of the mediators of apoptosis is p53 and several viruses produce proteins, such as the papovavirus large-T antigens, that are capable to subvert the function of p53. Since there is no evidence that polyomavirus large-T directly interacts with p53, it is tempting to speculate that in this virus middle-T ful®lls the role of an anti-apoptotic protein.
Materials and methods
Antibodies
Mouse monoclonal anti-middle-T Pab 762 was kindly provided by S Dilworth, London (Dilworth and Horner, 1993) , antibodies against p85 were from Dr M Thelen (Didichenko et al., 1996) and the antibody used to detect phosphatase 2A was raised against a 20 amino acid peptide derived from the amino terminus of the catalytic subunit of phosphatase 2A (B Hemmings, FMI).
Plasmids
The construction of the plasmid encoding a tagged form of PKB/Akt (HA-tagged human PKB a) under the control of a CMV promoter has been reported before (Alessi et al., 1996) . DPH-PKB/Akt was subcloned from the corresponding pECE vector HA-DNRac a into the same CMV based vector used throughout this study. Plasmids encoding the wild type (pcDNA3 HAp110) and kinase inactive (pcDNA3 HA-p110 R916P) catalytic subunit of PI 3-kinase were obtained from M Thelen, Bern (Didichenko et al., 1996) .
Tissue culture NIH3T3 cells were maintained in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% calf serum (CS) (GIBCO BRL).
Transient transfection
Transient transfections were performed with Lipofectamine (GIBCO BRL). 12 mg of plasmid DNA in 1 ml DMEM were mixed with 50 ml Lipofectamine in 1 ml DMEM for 15 min at room temperature. This mixture plus an additional 2 ml DMEM were added to one million cells in a 10 cm dish. Cells were incubated for 4 h and then the medium was changed to 10% CS DMEM for 12 h.
Immunoprecipitation
A 10 cm dish was lysed on ice with 500 ml lysis buer (25 mM Tris pH 7.6 at RT, 100 mM NaCl, 10 mM NaF, 1 mM Vanadate, 25 mM b-glycerophosphate, 3 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 1% NP40, 10% Glycerol, 1 mM DTT). The lysate was precleared by adding 20 ml Pansorbin (Calbiochem) followed by centrifugation. 50 ml of a 1 : 1 slurry of Protein A beads in lysis buer together with 1 mg antibody were added to 200 ml supernatant and rocked on ice for 1 h. The beads were washed 26 with lysis buer and 26 with kinase buer (25 mM MOPS pH 7.4 at RT, 25 mM b-glycerophosphate, 20 mM magnesium chloride, 1 mM DTT).
In vitro kinase assay
Pab 762 middle-T immunoprecipitates collected on beads were incubated with 75 ml kinase buer containing 1 mCi [g-32 P]ATP for 10 min at 308C. The reaction was stopped by the addition of 25 ml 46 sample buer and boiled for 5 min. PKB/Akt activity was measured in immunecomplex kinase assays following immunoprecipitation with the anti-HA-tag antibody. The beads were incubated with 75 ml kinase buer containing 5 mCi [g-32 P]ATP, 5 mM cold ATP and 5 mg histone 2B as substrate. The reaction was stopped after 10 min by the addition of 25 ml 46 sample buer and boiled for 5 min. The samples were separated by SDS ± PAGE (12.5%), blotted to a PVDF membrane (Millipore) and exposed to a phosphorimager cassette (Molecular Dynamics) for quantitation of the radioactivity incorporated into histone 2B. PKB/Akt was detected by Western blotting with the anti-HA-tag antibody and quantitated after scanning. To calculate the relative activity of PKB/ Akt, the quanti®ed kinase activities were divided by the amount of PKB/Akt determined using Western analysis and normalized to the value for unstimulated cells. Western analysis PVDF membranes were immunodecorated following standard Western blotting protocols. For detection of the primary antibody either an alkaline phosphatase-linked secondary antibody (Southern Biotechnology Associates) or an alkaline phosphatase protein A conjugate (Calbiochem) was used. The membranes were either developed using a colorimetric assay with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Boehringer Mannheim) or the chemiluminescent substrate CDP-Star manufactured by TROPIX.
